We are international
Donate
• about myeloma TEXT SIZE   
relapse    back

STEPS 9 & 10: REFERENCES FOR RELAPSE - DO YOU NEED A CHANGE IN TREATMENT? AND NEW TRIALS: HOW TO FIND THEM
04.01.13

STEPS 9 & 10- REFERENCES

  1. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents. Mohty Leukemia (2012) 26, 73-85
  2. Guidelines for supportive care in multiple myeloma 2011 British Journal of Hematology 2011 Blackwell Publishing Ltd, British Journal of Haematology, 154, 76-103
  3. Treatment of multiple myeloma. Rajkumar, S. V. Nat. Rev. Clin. Oncol. 8, 479-491 (2011); published online 26 April 2011; corrected online 6 July 2011; doi:10.1038/nrclinonc.2011.63
  4. Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma Constantine S. Mitsiades, Journal of Clinical Oncology VOLUME 29 _ NUMBER 14 _ MAY 10 2011
  5. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions Massimo Offidani, Expert Opin. Investig. Drugs (2011) 20(6):779-793
  6. Clinical Course of Patients With Relapsed Multiple Myeloma, Kumar Mayo Clin Proc. 2004;79(7):867-874
  7. Treatment Options for Relapsed and Refractory Multiple Myeloma, Richardson Clin Cancer Res 2011;17:1264-1277.
  8. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Dimopoulos European Journal of Haematology 86 (1-15) 2010
  9. Treatment of relapsed and refractory multiple myeloma in the era of novel agents Niels W.C.J. van de Donk, Cancer Treatment Reviews 37 (2011) 266-283
  10. Clinical Course of Patients With Relapsed Multiple Myeloma Mayo Clin Proc. • July 2004;79(7):867-874 • www.mayo.edu/proceedings
  11. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Kumar Leukemia (2012) 26, 149-157
  12. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Fernandez de Larrea et al.  Leukemia (2012), 1-12.
  13. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Arnulf et al.  Haematologica 2012; 97 (12): 1925-1928.

 related articles